This half-day workshop is aimed at those who are interested in developing a neuro-oncology clinical trial but are at the early stages of that journey. The session will take participants through the process of moving from an initial idea to a coherent, well-framed trial concept.
Through a combination of presentations and interactive breakout activities, participants will explore:
Chair
Neuropathologist (NSW)
Dr Laveniya Satgunaseelan is a pathologist in the Department of Neuropathology at Royal Prince Alfred Hospital, Sydney. Her main role is in the provision of molecular neuropathology services. She is the current secretary/treasurer of the Australia and New Zealand Society for Neuropathology. Her interests include cancer genomics and health equity in pathology.
Chair
Specialist Radiation Oncologist (VIC)
Joe is a Specialist Radiation Oncologist at the Peter MacCallum Cancer Centre, Melbourne, Australia. He did his medical training in New Zealand and radiation oncology training in Australia and holds a laboratory-based PhD in tumour immunology from the University of Melbourne. He is passionate about optimising the application of radiation therapy in modern multi-modal oncology paradigms and education of junior radiation oncology trainees.
Speaker
Medical Oncologist (VIC)
Prof. Gan graduated from Melbourne University with a Bachelor of Medicine and Surgery. In 2016, he was appointed the head of the Cancer Clinical Trials Unit at Austin Health. He is Adjunct Professor with Latrobe University. From 2020-2024, he was Clinical Research Lead at the Olivia Newton- John Cancer Research Institute (ONJCRI) and joined the ONJCRI Executive Team overseeing research across the ONJCRI.
He is a very active clinician scientist. He obtained his PhD from Melbourne University. In 2019, he formed and is the Head of the Cancer Therapies and Biology Group at ONJCRI, focused on the development of better cancer treatments, particularly brain cancer. He has had continuous grant success since 2015 and over 170 peer reviewed journals including in Nature, Journal of Clinical Oncology and Neuro-Oncology, the leading global journals in science, clinical oncology and neuro-oncology respectively.
He is passionate about improving the outcomes for patients with brain cancer. In particular, he has helped lead multiple clinical trials in brain cancer, including trials using drugs from the ONJCRI research program such as mAb806 (subsequently developed into ABT-414) and ifabotuzumab, one of the first drugs specifically targeting the tumour microenvironment. He co-founded the Australian Brain Cancer Research Alliance (ABCARA) and is the study chair for the LUMOS-1 and LUMOS-2 platform trials in recurrent IDH-mutant glioma.
Speaker
Medical Oncologist (NSW)
A/Prof Hao-Wen Sim is a Sydney-based medical oncologist specialising in adult neuro-oncology and biostatistics. A graduate with Honours from the University of Melbourne (receiving the James Stewart Bequest for Surgery and a place on the Margaret Whyte Honour Board), he also holds a Master of Biostatistics from the University of Sydney, where he earned multiple prestigious accolades, including the Biostatistics Collaboration of Australia Star Graduate Award. He further honed his expertise with a neuro-oncology fellowship at the Princess Margaret Cancer Centre in Toronto. A/Prof Sim plays key roles in advancing brain cancer research as Deputy Chair of the COGNO Scientific Advisory Committee, Chair of the International Clinical Research Subcommittee, and Clinical Lead for COGNO at the NHMRC Clinical Trials Centre. His clinical practice includes treating neuro-oncology patients at The Kinghorn Cancer Centre and Chris O’Brien Lifehouse. His research focuses on the development and implementation of national brain cancer trials.
Speaker
Medical Oncologist (NSW)
Dr Alex Yuile is a Medical Oncologist with a keen interest in primary brain tumours. After completing his fellowship in neuro-oncology and translational research at Royal North Shore Hospital he began his PhD focusing on IDH-mutant gliomas. Dr Yuile is currently working as a neuro-oncologist at Royal North Shore Hospital and has particular interest in IDH-mutant gliomas and neuro-oncology clinical trials. He is a member of the Scientific Advisory Committee for the Co-operative Trials Group for Neuro-Oncology and the EviQ Neuro-Oncology Reference Committee.
Education Events
Education Events
Education Events
